Dara Biosciences (DARA) 0.88 $DARA
DARA BioSciences wins stockholder's approval of merger with and into Midatech
M2 - Thu Dec 03, 5:27AM CST
DARA BioSciences (NasdaqCM
ARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Stockholder Approval of Merger With Midatech
Marketwired - Wed Dec 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC ("Midatech"
and certain other parties thereto.
DARA: 0.88 (-0.06)
DARA BioSciences posts higher loss of USD2.7m for Q3 2015
M2 - Tue Nov 03, 4:21AM CST
Pharmaceutical company DARA BioSciences (NasdaqCMARA) disclosed on Monday that it recorded a loss attributable to controlling interest of approximately USD2.7m (USD0.14 per share) for the third quarter ended 30 September 2015.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Third Quarter 2015 Results
Marketwired - Mon Nov 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
Marketwired - Tue Oct 06, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature growth companies in Healthcare, Technology, Telecom and Aerospace-Defense sectors, will be held October 7-9, 2015 at The Encore at Wynn Hotel in Las Vegas, NV. DARA BioSciences is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.
DARA: 0.88 (-0.06)
DARA BioSciences unveils Oravig (miconazole) in the oncology and primary care markets in the US for treatment of adults with oral thrush
M2 - Tue Oct 06, 4:36AM CDT
Specialist pharmaceutical company DARA BioSciences (NasdaqCMARA) reported on Monday the availability of Oravig, the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, into the oncology and primary care markets in the US.
DARA: 0.88 (-0.06)
DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
Marketwired - Mon Oct 05, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today the U.S. launch of Oravig -- the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush -- into the Oncology and Primary Care markets. Beginning this week, DARA and its marketing partner Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, TX, will simultaneously begin promotion of Oravig with two separate sales forces focusing on the highest prescribing physicians of oral thrush therapy; DARA will promote Oravig exclusively in Oncology with its 20 person nationwide sales force and Mission will utilize its 40 person-strong sales team to promote the product exclusively to the Primary Care market. DARA was granted exclusive U.S. rights to Oravig in March 2015, under a Commercialization Agreement with Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
Marketwired - Wed Sep 23, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2015 Healthcare conference. The conference is being held September 29, 2015, at the Sofitel Hotel in New York City.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
Marketwired - Wed Sep 02, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Rodman and Renshaw Global Investment Conference. The conference is being held September 8-10, 2015, at the Saint Regis Hotel in New York City.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Second Quarter 2015 Results
Marketwired - Wed Aug 12, 3:15PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
Marketwired - Mon Aug 10, 7:00AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.
DARA: 0.88 (-0.06)
Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests
PR Newswire - Thu Jun 25, 2:49PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of DARA BioSciences Inc. (NASDAQ: DARA) by Midatech Pharma Plc (London: MTPH). On June 4, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Midatech will acquire DARA. Under the terms of the agreement, DARA shareholders will receive 0.272 shares of Midatech for each share of DARA they own, the value of which is equivalent to $1.20 per share of DARA common stock.
DARA: 0.88 (-0.06)
DARA BioSciences wins stockholder's approval of merger with and into Midatech
M2 - Thu Dec 03, 5:27AM CST
DARA BioSciences (NasdaqCM
ARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto. DARA: 0.88 (-0.06)
DARA BioSciences Announces Stockholder Approval of Merger With Midatech
Marketwired - Wed Dec 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC ("Midatech"
and certain other parties thereto. DARA: 0.88 (-0.06)
DARA BioSciences posts higher loss of USD2.7m for Q3 2015
M2 - Tue Nov 03, 4:21AM CST
Pharmaceutical company DARA BioSciences (NasdaqCM
ARA) disclosed on Monday that it recorded a loss attributable to controlling interest of approximately USD2.7m (USD0.14 per share) for the third quarter ended 30 September 2015. DARA: 0.88 (-0.06)
DARA BioSciences Announces Third Quarter 2015 Results
Marketwired - Mon Nov 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
Marketwired - Tue Oct 06, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature growth companies in Healthcare, Technology, Telecom and Aerospace-Defense sectors, will be held October 7-9, 2015 at The Encore at Wynn Hotel in Las Vegas, NV. DARA BioSciences is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.
DARA: 0.88 (-0.06)
DARA BioSciences unveils Oravig (miconazole) in the oncology and primary care markets in the US for treatment of adults with oral thrush
M2 - Tue Oct 06, 4:36AM CDT
Specialist pharmaceutical company DARA BioSciences (NasdaqCM
ARA) reported on Monday the availability of Oravig, the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, into the oncology and primary care markets in the US. DARA: 0.88 (-0.06)
DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
Marketwired - Mon Oct 05, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today the U.S. launch of Oravig -- the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush -- into the Oncology and Primary Care markets. Beginning this week, DARA and its marketing partner Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, TX, will simultaneously begin promotion of Oravig with two separate sales forces focusing on the highest prescribing physicians of oral thrush therapy; DARA will promote Oravig exclusively in Oncology with its 20 person nationwide sales force and Mission will utilize its 40 person-strong sales team to promote the product exclusively to the Primary Care market. DARA was granted exclusive U.S. rights to Oravig in March 2015, under a Commercialization Agreement with Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
Marketwired - Wed Sep 23, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2015 Healthcare conference. The conference is being held September 29, 2015, at the Sofitel Hotel in New York City.
DARA: 0.88 (-0.06)
DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
Marketwired - Wed Sep 02, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Rodman and Renshaw Global Investment Conference. The conference is being held September 8-10, 2015, at the Saint Regis Hotel in New York City.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Second Quarter 2015 Results
Marketwired - Wed Aug 12, 3:15PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results.
DARA: 0.88 (-0.06)
DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
Marketwired - Mon Aug 10, 7:00AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.
DARA: 0.88 (-0.06)
Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests
PR Newswire - Thu Jun 25, 2:49PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of DARA BioSciences Inc. (NASDAQ: DARA) by Midatech Pharma Plc (London: MTPH). On June 4, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Midatech will acquire DARA. Under the terms of the agreement, DARA shareholders will receive 0.272 shares of Midatech for each share of DARA they own, the value of which is equivalent to $1.20 per share of DARA common stock.
DARA: 0.88 (-0.06)
